Neurology
Conference Coverage
Positive functional results reported for aducanumab in a pooled, post hoc analysis
SAN DIEGO – The results might give patients “an extra year or 2” of independence, said one clinical investigator in an aducanumab trial.
From the Journals
‘Brain enhancement’ supplements sold online may illegally contain piracetam
So-called cognitive enhancement supplements sold online may contain high doses of the nootropic drug piracetam.
From the Journals
Researchers describe first cases of episodic visual snow associated with migraine
A series of migraine patients with episodic visual snow makes case for a condition that is distinct from visual snow syndrome.
From the Journals
Ubrogepant may relieve migraine pain at 2 hours
More patients who received the oral CGRP receptor antagonist were free of pain 2 hours later, compared with patients who received placebo,...
Feature
Seaweed floats to the top of Alzheimer’s news
Chinese regulators have approved sodium oligomannate, an extract of brown algae, as a treatment for mild to moderate Alzheimer’s. But questions...
News
Survey asks adults: How likely are you to develop dementia?
Adults are worried about dementia and will do anything to prevent it. Except talk to their doctor.
Conference Coverage
Reappraising standard treatment of comorbid insomnia/depression
COPENHAGEN – “There are some effects on insomnia when you treat depression, but they’re not very large.”
News from the FDA/CDC
Fentanyl-related deaths show strong regional pattern
Overdose death rates for cocaine, heroin, and fentanyl are high in the East and low in the West.
Feature
Medicare beneficiaries pay most for Alzheimer’s
Long-term care takes a toll on beneficiaries with Alzheimer’s and Parkinson’s disease.
Conference Coverage
Blood test might rival PET scan for detecting brain amyloidosis
ST. LOUIS – A blood test that measures the plasma ratio of amyloid-beta 42 peptide to amyloid-beta peptide 40 can accurately screen cognitively...
Feature
Dr. Paul Aisen Q&A: Aducanumab for Alzheimer’s
A leading Alzheimer’s researcher, Dr. Aisen answers some questions about the resurrection of aducanumab as a potential therapy for Alzheimer’s...